Lenalidomide and subsequent TP53-mutated myeloid neoplasms, abnormal uterine bleeding after VTE, and novel tri-specific antibody for B-ALL
Blood Podcast
00:00
TP53 Mutated Myeloid Neoplasms - A Review
Study looked at 416 patients with solid tumors or non-myeloid humanologic malignancies. Lenalidomide accounted for 92% of phelidomide analog exposure in their cohort. The median time from treatment to diagnosis of myeloid neoplasm was 6.2 years. At least one gene mutation detected in 85% of patients.
Transcript
Play full episode
